177P Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)

Autor:	C-J. Tan, Yuhong Chen, H-C. Sun, Jianwei Fan, J. Zhou, C. Huang, X. Zhu, Y-H. Shen, D. Wu, N-L. Ge
Rok vydání:	2020
Předmět:	biology business.industry First line Anti pd 1 Hematology medicine.disease Tumour response chemistry.chemical_compound Oncology chemistry Hepatocellular carcinoma Organ specific medicine biology.protein Cancer research In patient Antibody business Lenvatinib
Zdroj:	Annals of Oncology. 31:S1308
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.10.198
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::068ef9d87e9f586ff9f1736fae5ee711 https://doi.org/10.1016/j.annonc.2020.10.198 Zobrazit plný text záznamu